3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Brain Neoplasms
23
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
14
Carcinoma, Hepatocellular
11
Lung Neoplasms
10
Prostatic Neoplasms
9
Breast Neoplasms
5
Neoplasms
4
Melanoma
3
Carcinoma, Renal Cell
3
Small Cell Lung Carcinoma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Stage II Prostate Adenocarcinoma AJCC v7
1
Sarcoma, Ewing
1
Radiation Therapy
1
Radiation Injuries
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic
1
Pituitary Neoplasms
1
Patients Receiving Fractionated Stereotactic Radiotherapy
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Oligometastatic Hormone Sensitive Prostate Cancer
1
Neurotoxicity Syndromes
1
Neuroma, Acoustic
1
Nasopharyngeal Carcinoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Growth Hormone-Secreting Pituitary Adenoma
1
Interventions
enzalutamide
2
cabazitaxel
2
Prednisone
2
Androgen Antagonists
2
fludrocortisone acetate
1
darolutamide
1
XRP6258
1
Radiosurgery
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostate Cancer Metastatic
×
Radiosurgery
×
Clear all
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled